Evaluation of patients diagnosed with psoriasis and multiple myeloma after autologous stem cell transplantation

The secretion of monoclonal immunoglobulins increase in chronic inflammatory disorders such as chronic infections and autoimmune diseases. This risk is further increased by the biological agents used in the treatment of autoimmune diseases such as psoriasis. Hematological malignancies occurring in p...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion and apheresis science 2021-08, Vol.60 (4), p.103137-103137, Article 103137
Main Authors: Ugur, Mehmet Can, Gediz, Füsun
Format: Article
Language:English
Subjects:
Aged
Autografts
Female
Follow-Up Studies
Humans
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - therapy
PASI score
Psoriasis
Psoriasis - diagnosis
Psoriasis - therapy
Stem cell transplant
Stem Cell Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The secretion of monoclonal immunoglobulins increase in chronic inflammatory disorders such as chronic infections and autoimmune diseases. This risk is further increased by the biological agents used in the treatment of autoimmune diseases such as psoriasis. Hematological malignancies occurring in patients with psoriasis provides an opportunity to evaluate the effect of autologous or allogeneic stem cell transplantation in this immune-mediated disease. Four patients diagnosed with psoriasis are presented, having undergone autologous bone marrow transplantation (ABMT), and eventually having remission of their psoriasis, after developing multiple myeloma during follow up. Psoriasis history of the patients was 20, 23, 2 and 2 years, respectively. All of them received peroral methotrexate or topical corticosteroid therapy. Time until myeloma diagnosis were 220, 144, 25, 18 months and follow-up after ABMT were 26, 19, 15, 22 months, respectively Psoriasis can be effectively treated with stem cell transplantation that is used in the treatment of malignancies. For this reason, stem cell transplantation can be considered as a treatment option in these patients, considering the benefit-to-harm ratio. However, uncertainty continues regarding the autologous or allogeneic application of stem cell transplantation
ISSN:1473-0502
1878-1683
DOI:10.1016/j.transci.2021.103137